PL3320912T3 - Immunoterapia na bazie 2,3-dioksygenazy indoloaminy - Google Patents

Immunoterapia na bazie 2,3-dioksygenazy indoloaminy

Info

Publication number
PL3320912T3
PL3320912T3 PL17194619T PL17194619T PL3320912T3 PL 3320912 T3 PL3320912 T3 PL 3320912T3 PL 17194619 T PL17194619 T PL 17194619T PL 17194619 T PL17194619 T PL 17194619T PL 3320912 T3 PL3320912 T3 PL 3320912T3
Authority
PL
Poland
Prior art keywords
indoleamine
based immunotherapy
dioxygenase
dioxygenase based
immunotherapy
Prior art date
Application number
PL17194619T
Other languages
English (en)
Inventor
Mads Hald Andersen
Per Thor Straten
Original Assignee
Io Biotech Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Io Biotech Aps filed Critical Io Biotech Aps
Publication of PL3320912T3 publication Critical patent/PL3320912T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0069—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y113/00—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13)
    • C12Y113/11—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13) with incorporation of two atoms of oxygen (1.13.11)
    • C12Y113/11052—Indoleamine 2,3-dioxygenase (1.13.11.52), i.e. indoleamine 2,3-dioxygenase 1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PL17194619T 2008-04-17 2009-04-17 Immunoterapia na bazie 2,3-dioksygenazy indoloaminy PL3320912T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200800565 2008-04-17
PCT/DK2009/000095 WO2009143843A1 (en) 2008-04-17 2009-04-17 Indoleamine 2, 3-dioxygenase based immunotherapy
EP17194619.7A EP3320912B1 (en) 2008-04-17 2009-04-17 Indoleamine 2, 3-dioxygenase based immunotherapy
EP09753556.1A EP2280721B1 (en) 2008-04-17 2009-04-17 Indoleamine 2, 3-dioxygenase based immunotherapy

Publications (1)

Publication Number Publication Date
PL3320912T3 true PL3320912T3 (pl) 2021-10-25

Family

ID=40873320

Family Applications (2)

Application Number Title Priority Date Filing Date
PL17194619T PL3320912T3 (pl) 2008-04-17 2009-04-17 Immunoterapia na bazie 2,3-dioksygenazy indoloaminy
PL09753556T PL2280721T3 (pl) 2008-04-17 2009-04-17 Immunoterapia na bazie 2,3-dioksygenazy indoloaminy

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL09753556T PL2280721T3 (pl) 2008-04-17 2009-04-17 Immunoterapia na bazie 2,3-dioksygenazy indoloaminy

Country Status (20)

Country Link
US (6) US9433666B2 (pl)
EP (3) EP3320912B1 (pl)
JP (2) JP2011520783A (pl)
CN (2) CN104056261B (pl)
AU (1) AU2009253539B2 (pl)
CA (1) CA2721150C (pl)
CY (2) CY1120352T1 (pl)
DK (2) DK3320912T3 (pl)
ES (2) ES2657963T3 (pl)
HR (2) HRP20180282T1 (pl)
HU (2) HUE055338T2 (pl)
IL (1) IL208781A (pl)
LT (2) LT3320912T (pl)
NO (1) NO2280721T3 (pl)
NZ (1) NZ588757A (pl)
PL (2) PL3320912T3 (pl)
PT (2) PT2280721T (pl)
SI (2) SI3320912T1 (pl)
WO (1) WO2009143843A1 (pl)
ZA (1) ZA201008056B (pl)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3320912T (lt) 2008-04-17 2021-07-12 Io Biotech Aps Indolamino 2,3-dioksigenaze grindžiama imunoterapija
EP2425830A1 (en) * 2010-09-03 2012-03-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Synergistic drug combination for the treatment of cancer
GB201315946D0 (en) * 2013-09-06 2013-10-23 Immune Targeting Systems Its Ltd Oncology vaccine
WO2015181266A1 (en) * 2014-05-29 2015-12-03 Spring Bioscience Corporation Anti- indoleamine 2,3-dioxygenase 1 antibodies and diagnostic uses thereof
PT3193917T (pt) 2014-09-17 2021-10-20 Io Biotech Aps Composições de vacina compreendendo triptofano-2,3-dioxigenase ou fragmentos desta
CN106148276A (zh) * 2015-04-16 2016-11-23 中国科学院上海生命科学研究院 间充质干细胞在制备治疗神经退行性疾病的药物中的应用
KR20180021882A (ko) 2015-06-29 2018-03-05 오제 이뮈노테라프틱스 짧은 펩타이드 항-암 백신을 이용하여 초기 t 기억 반응을 유도하는 방법
CN116333088A (zh) 2015-09-16 2023-06-27 Io生物技术公司 包含c-c基序趋化因子22（ccl22）或其片段的疫苗组合物
ES2965009T3 (es) 2016-03-04 2024-04-10 Io Biotech Aps Terapia combinada contra el cancer
CA3026572A1 (en) 2016-06-10 2017-12-14 Io Biotech Aps Calr and jak2 vaccine compositions
JP2019537432A (ja) * 2016-10-04 2019-12-26 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド 標的化エフェクタータンパク質およびその使用
CA3038184A1 (en) * 2016-10-14 2018-04-19 Universitat Zurich Indoleamine-2,3-dioxygenase assay for prostate cancer diagnosis and prognosis
JP2020506901A (ja) * 2017-01-20 2020-03-05 アタラ バイオセラピューティクス，インコーポレーテッド 自家ｔ細胞を用いた多発性硬化症の処置方法
NZ754139A (en) 2017-01-27 2022-07-01 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
EA201991444A1 (ru) 2017-01-27 2019-12-30 Имматикс Байотекнолоджиз Гмбх Новые пептиды и комбинации пептидов для применения в иммунотерапии рака яичника и других видов рака
TWI796314B (zh) * 2017-01-27 2023-03-21 德商英麥提克生物技術股份有限公司 用於卵巢癌和其他癌症免疫治療的新型肽和肽組合物
US11407797B2 (en) 2017-10-11 2022-08-09 University Of Florida Research Foundation, Incorporated Modified gal-1 proteins and uses thereof
BR112020010656A2 (pt) 2017-11-27 2020-11-10 Ose Immunotherapeutics tratamento aprimorado de câncer
CN109758467B (zh) * 2019-03-08 2020-12-25 中国农业科学院兰州兽医研究所 一种吉西他滨在制备预防口蹄疫病毒感染的药物中的应用
JP2022554217A (ja) * 2019-10-23 2022-12-28 ザ・カウンシル・オヴ・ザ・クイーンズランド・インスティテュート・オヴ・メディカル・リサーチ 養子免疫療法
CN112881269A (zh) * 2021-02-23 2021-06-01 浙江正熙生物技术股份有限公司 一种流式荧光检测试剂的质量检测方法
GB202103673D0 (en) 2021-03-17 2021-04-28 Io Biotech Aps Combination therapy for cancer
WO2023161350A1 (en) 2022-02-24 2023-08-31 Io Biotech Aps Nucleotide delivery of cancer therapy
CN114657158B (zh) * 2022-05-25 2022-10-21 深圳吉诺因生物科技有限公司 Ido1相关疫苗及其应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US58767A (en) 1866-10-16 John brougjbton
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
WO1997000966A1 (en) * 1995-06-20 1997-01-09 Merck & Co., Inc. Conversion of indene to (1s)-amino-(2r)-indanol free of any stereoisomer, by combination of dioxygenase bioconversion and chemical steps
US6096313A (en) 1996-02-09 2000-08-01 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
CN1221349A (zh) 1996-06-12 1999-06-30 郭亚军 细胞疫苗、免疫治疗以及它们的制备方法
CN1223688A (zh) * 1996-06-27 1999-07-21 纳幕尔杜邦公司 对羟基苯丙酮酸双加氧酶的植物基因
DE19730066A1 (de) * 1997-07-14 1999-01-21 Basf Ag DNA-Sequenz codierend für eine Hydroxyphenylpyruvatdioxygenase und deren Überproduktion in Pflanzen
WO1999029310A2 (en) 1997-12-05 1999-06-17 Medical College Of Georgia Research Institute, Inc. Regulation of t cell-mediated immunity by tryptophan and its analogs
WO2000066764A1 (en) 1999-05-03 2000-11-09 Ludwig Institute For Cancer Research Methods for increasing t cell proliferation
EP1425302A2 (en) 2001-01-24 2004-06-09 Protein Design Labs Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
US20030087250A1 (en) 2001-03-14 2003-05-08 Millennium Pharmaceuticals, Inc. Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
WO2003012061A2 (en) 2001-08-01 2003-02-13 Coley Pharmaceutical Gmbh Methods and compositions relating to plasmacytoid dendritic cells
AU2002361468A1 (en) 2001-08-14 2003-03-18 The Government Of The United States Of America As Represented By The Secretary Of Health And Human S Method for rapid generation of mature dendritic cells
US20060292618A1 (en) 2002-04-12 2006-12-28 Mellor Andrew L Antigen-presenting cell populations and their use as reagents for enhancing or reducing immune tolerance
AU2002307243B2 (en) 2002-04-12 2008-01-03 Medical College Of Georgia Research Institute, Inc. Antigen-presenting cell populations and their use as reagents for enhancing or reducing immune tolerance
DE10229872A1 (de) * 2002-07-03 2004-01-29 Curevac Gmbh Immunstimulation durch chemisch modifizierte RNA
WO2004048938A2 (en) 2002-11-26 2004-06-10 Protein Design Labs, Inc. Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
WO2004053075A2 (en) 2002-12-05 2004-06-24 Diadexus, Inc. Compositions, splice variants and methods relating to breast specific genes and proteins
PL377213A1 (pl) 2002-12-13 2006-01-23 Mitra Medical Technology Ab Antychłoniakowe środki ukierunkowujące z funkcjami efektorowymi i powinowactwa połączonymi trifunkcyjnym reagentem
DE10261223A1 (de) 2002-12-20 2004-07-08 MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH Steigerung der Immunantwort durch Substanzen, welche die Funktion von Natürlichen Killerzellen beeinflussen
EP2260846B1 (en) 2003-03-27 2018-11-28 Lankenau Institute for Medical Research Novel methods for the treatment of cancer
US7598287B2 (en) 2003-04-01 2009-10-06 Medical College Of Georgia Research Institute, Inc. Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities
US20050186289A1 (en) * 2003-04-01 2005-08-25 Medical College Of Georgia Research Institute, Inc. Regulation of T cell-mediated immunity by D isomers of inhibitors of indoleamine-2,3-dioxygenase
WO2005017163A2 (en) 2003-08-15 2005-02-24 Imperial College Innovations Limited Phenotypic knockout of cell-surface proteins
WO2005036127A2 (en) 2003-10-02 2005-04-21 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for identifying target cell cytolytic lymphocytes in a sample
JP2008505937A (ja) * 2004-07-13 2008-02-28 ザ ユニバーシティ オブ ブリティッシュ コロンビア インドールアミン２，３−ジオキシゲナーゼ（ｉｄｏ）阻害剤
WO2006056304A2 (en) 2004-11-23 2006-06-01 Institut Pasteur Control of indoleamine 2,3 deoxygenase expression and activity
KR20070108536A (ko) 2005-02-04 2007-11-12 수르벡 에이피에스 서바이빈 펩티드 백신
WO2006122150A1 (en) 2005-05-10 2006-11-16 Incyte Corporation Modulators of indoleamine 2,3-dioxygenase and methods of using the same
US7468186B2 (en) 2005-07-22 2008-12-23 City Of Hope Polyomavirus cellular epitopes and uses therefor
GB0519303D0 (en) 2005-09-21 2005-11-02 Oxford Biomedica Ltd Chemo-immunotherapy method
CN101313062A (zh) * 2005-09-23 2008-11-26 塞勒里克斯有限公司 具有免疫调节活性的细胞群及其分离方法和用途
US20070203140A1 (en) 2006-02-09 2007-08-30 Combs Andrew P N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase
WO2007115068A2 (en) 2006-03-30 2007-10-11 Indiana University Research And Technology Corporation Genetic variants in the indoleamine 2,3-dioxygenase gene
EP2023715B1 (en) * 2006-05-18 2014-01-08 Lankenau Institute for Medical Research Indoleamine-2, 3-dioxygenase-2
WO2008085828A2 (en) * 2007-01-03 2008-07-17 The Johns Hopkins University Peptide modulators of angiogenesis and use thereof
LT3320912T (lt) 2008-04-17 2021-07-12 Io Biotech Aps Indolamino 2,3-dioksigenaze grindžiama imunoterapija

Also Published As

Publication number Publication date
CA2721150C (en) 2017-09-26
WO2009143843A1 (en) 2009-12-03
JP2011520783A (ja) 2011-07-21
PT3320912T (pt) 2021-05-24
JP6016966B2 (ja) 2016-10-26
CN102088994B (zh) 2014-06-25
LT3320912T (lt) 2021-07-12
US20220249641A1 (en) 2022-08-11
NO2280721T3 (pl) 2018-04-14
CN104056261B (zh) 2017-01-11
HRP20210766T1 (hr) 2021-07-23
EP3320912B1 (en) 2021-03-31
EP2280721A1 (en) 2011-02-09
US11324813B2 (en) 2022-05-10
IL208781A (en) 2017-09-28
HUE037973T2 (hu) 2018-09-28
SI2280721T1 (en) 2018-02-28
JP2015129182A (ja) 2015-07-16
CN104056261A (zh) 2014-09-24
DK3320912T3 (da) 2021-05-31
IL208781A0 (en) 2010-12-30
DK2280721T3 (da) 2018-01-29
US20110318372A1 (en) 2011-12-29
EP3915570A1 (en) 2021-12-01
PL2280721T3 (pl) 2018-04-30
SI3320912T1 (sl) 2021-08-31
HUE055338T2 (hu) 2021-11-29
CY1124279T1 (el) 2022-07-22
LT2280721T (lt) 2018-02-12
CY1120352T1 (el) 2019-07-10
ES2657963T3 (es) 2018-03-07
US20220202922A1 (en) 2022-06-30
CN102088994A (zh) 2011-06-08
US9433666B2 (en) 2016-09-06
CA2721150A1 (en) 2009-12-03
HRP20180282T1 (hr) 2018-03-23
NZ588757A (en) 2012-05-25
AU2009253539B2 (en) 2014-03-20
ES2870596T3 (es) 2021-10-27
US11648302B2 (en) 2023-05-16
US20230233657A1 (en) 2023-07-27
EP3320912A1 (en) 2018-05-16
US10258678B2 (en) 2019-04-16
AU2009253539A1 (en) 2009-12-03
ZA201008056B (en) 2011-07-27
US20170049868A1 (en) 2017-02-23
PT2280721T (pt) 2018-02-16
EP2280721B1 (en) 2017-11-15
US20190201512A1 (en) 2019-07-04

Similar Documents

Publication Publication Date Title
ZA201008056B (en) Indoleamine 2,3-dioxygenase based immunotherapy
HRP20180662T1 (hr) 1,2,5-oksadiazoli kao inhibitori indolamin 2,3-dioksigenaze
ZA201205788B (en) 1,2,4-triazine-4-amine derivatives
SI2384326T1 (sl) Pirolo(2,3-d)pirimidinske spojine
EP2361902A4 (en) 4,6-DIAMINONICOTINSÄUREAMIDVERBINDUNG
EP2376105A4 (en) NKG2D-FC FOR IMMUNOTHERAPY
EP2377874A4 (en) Antioxidant
EP2351732A4 (en) NEW RAMALINE CONNECTION AND ITS USE
ZA201008657B (en) 4,5-dihydro-oxazol-2-yl derivatives
MY165626A (en) 1,2,4,-triazolone derivative
PL2234635T3 (pl) Immunoterapia oparta na białkach rhoc
SI2266990T1 (sl) Spojina 3-fenilpirazolo(5,1-b)tiazola
IL213762A0 (en) 1,1,1-trifluoro-2-hydroxypropyl compounds
AP2744A (en) Phenanthrenone compounds, compositions and methods
HK1161684A1 (en) 5,6-dihydro-1h-pyridin-2-one compounds 56- -1h--2-
GB2461167B (en) Novel amidoxime derivatives